5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline | 871465-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline
• CAS: 871465-04-2
• 化学式: C₂₃H₄₀N₄
• 分子量: 372.597
• InChiKey: PKYYDMJWPHSXBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  30.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline 、 3-溴-4-氯-1H-吡唑啉并嘧啶 在 N,N-二异丙基乙胺 作用下， 以 异丙醇 为溶剂， 反应 2.0h， 生成 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
  参考文献：
  名称：

  Pyrazolopyrimidines as dual Akt/p70S6K inhibitors

  摘要：

  Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.011
• 作为产物：
  描述：

  3,5-二溴-4-甲基苯酚 在 盐酸 、 甲醇 、 bis-triphenylphosphine-palladium(II) chloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 copper(l) iodide 、 palladium on activated charcoal 、 氢气 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 三乙胺 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 66.53h， 生成 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline
  参考文献：
  名称：

  Pyrazolopyrimidines as dual Akt/p70S6K inhibitors

  摘要：

  Activation of the PI3K/Akt/mTOR kinase pathway is frequently associated with human cancer. Selective inhibition of p70S6Kinase, which is the last kinase in the PI3K pathway, is not sufficient for strong tumor growth inhibition and can lead to activation of upstream proteins including Akt through relief of a negative feedback loop. Targeting multiple sites in the PI3K pathway might be beneficial for optimal activity. In this manuscript we report the design of dual Akt/p70S6K inhibitors and the evaluation of the lead compound 11b in vivo, which was eventually advanced into clinical development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.011